Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.00959-19. Print 2019 Nov.
The activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high. The remaining isolates had rifampin MICs of ≤0.016 μg/ml, and the rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm bactericidal concentrations (MBBC) for ≥50% of isolates were 8, 1, 2, and 4 μg/ml (for ) and 2, 0.06, 0.25, and 0.5 μg/ml (for ), respectively, for rifampin-susceptible isolates. Nonrifampin rifamycins have promising staphylococcal activity, including antibiofilm activity.
研究了利福平、利福布汀、利福喷丁和利福昔明对 200 株假体周围关节感染（PJI）相关葡萄球菌的活性。7 株耐利福平的分离株的 MIC 值≥4μg/ml。3 株分离株的利福平 MIC 值为 0.25 至 1μg/ml，且携带 Asp471Gly RpoB 变异体，表明 CLSI 利福平敏感葡萄球菌的折点≤1μg/ml 可能过高。其余分离株的利福平 MIC 值≤0.016μg/ml，≥50%分离株的利福平、利福布汀、利福喷丁和利福昔明最低生物膜杀菌浓度（MBBC）分别为 8、1、2 和 4μg/ml（利福平敏感分离株）和 2、0.06、0.25 和 0.5μg/ml（利福平敏感分离株）。非利福平类利福霉素对葡萄球菌具有良好的活性，包括抗生物膜活性。
